Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
View the Latest: Build Back Better
Filter
-
-
Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
Issue BriefThis data note describes Medicaid prescription drug utilization and spending trends in calendar year 2020 compared to previous years to explore how the pandemic impacted Medicaid prescription drug utilization and spending.
-
Maternal Health in the Build Back Better Act
Policy WatchThis policy watch highlights the different provisions and potential impact on parents and children in America. From expanding Medicaid postpartum coverage to establishing a national paid family leave policy, the BBBA could provide more support to states and community organizations working to improve maternal health.
-
New KFF Resource Explains Key Provisions for Maternal Health Within the Build Back Better Act
News ReleaseIf passed, the Build Back Better Act (BBBA) would include several provisions to improve maternal health, particularly for people of color. A new KFF Policy Watch explains the different provisions, their potential impact on parents and children, as well as the projected federal costs of these proposals.
-
Without Build Back Better, Will the End of the Public Health Emergency Leave Even More People Uninsured?
Policy WatchContinuous enrollment in Medicaid and enhanced premium assistance have helped millions afford and maintain coverage, but those gains could be reversed as the public emergency ends and if the provisions like those in the Build Back Better Act fail to pass.
-
Medicare Part B Drugs: Cost Implications for Beneficiaries in Traditional Medicare and Medicare Advantage
Issue BriefIn the face of rising prescription drug costs, a large majority of the public supports federal efforts to lower drug spending. Policymakers are considering several proposals that would lower prescription drug costs. To better understand the potential out-of-pocket cost exposure that Medicare beneficiaries may face for Part B drugs, which are typically administered by physicians and other health care providers, we analyzed cost-sharing liability for these drugs in traditional Medicare and cost-sharing requirements in Medicare Advantage plans.